← Back to Companies

HeartFlow

Medical technology company providing AI-powered non-invasive coronary artery disease diagnostics using personalized 3D heart models and computational fluid dynamics.

Location
Mountain View, California, USA
Founded
2007
Categories
medical-technology, cardiovascular, ai-diagnostics, imaging

Notes

HeartFlow is a medical technology company specializing in precision heart care through AI-driven cardiovascular imaging solutions. The company's flagship product, HeartFlow FFRCT Analysis, uses data from a standard coronary CT scan to create a personalized 3D model of the coronary arteries and assess the impact of blockages on blood flow using computational fluid dynamics.

HeartFlow went public on Nasdaq (ticker: HFLO) in August 2025, achieving a $2.27 billion valuation in its debut. Prior to the IPO, the company raised $98 million in convertible notes financing.

Team

  • John Farquhar - President, Chief Executive Officer & Board Director
  • Charles A. Taylor, Ph.D. - Founder & Chief Technology Officer
  • Campbell Rogers, M.D. - Chief Medical Officer
  • Angela Ahmad - Chief Legal & Compliance Officer

Additional Research Findings

  • Backed by Bain Capital Life Sciences
  • FDA-cleared non-invasive FFR technology
  • FFRCT Analysis creates personalized 3D coronary models
  • Uses computational fluid dynamics to assess blood flow
  • Over 1 million patients analyzed globally
  • Nasdaq IPO August 2025, valued at $2.27 billion
  • Raised $98 million in convertible notes (pre-IPO)
  • Technology eliminates need for invasive catheterization in many cases

Sources